Skip to contentpdufa.bio

LB2501 (in vivo CD19/CD20 dual-targeting CAR-T)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) is a Legend Biotech Corp program in relapsed/refractory B-cell non-Hodgkin lymphoma. Its next catalyst is a Readout on Dec 13, 2026.

LEGN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Relapsed/refractory B-cell non-Hodgkin lymphoma. Sponsor: Legend Biotech Corp (LEGN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 13, 2026LEGN

Questions

When is LB2501 (in vivo CD19/CD20 dual-targeting CAR-T)'s next FDA decision or readout?

The next tracked catalyst for LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) is a Readout on Dec 13, 2026.

What happened at LB2501 (in vivo CD19/CD20 dual-targeting CAR-T)'s most recent FDA decision?

No FDA decision for LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) is in our archive yet.

What is LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) used for?

In our records LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) is under review or in development for Relapsed/refractory B-cell non-Hodgkin lymphoma.

Who makes LB2501 (in vivo CD19/CD20 dual-targeting CAR-T)?

Legend Biotech Corp (LEGN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.